Nierengarten

Avrobio Inc (NASDAQ: AVRO), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million shares in an IPO. With the analyst quiet period expiring, the sell-side began initiating...